AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 426-436

  Cirelli, J A ^a   Park, C H ^a,b   MacKool, K ^a   Taba Jr , M ^a   Lustig, K H ^c   Burstein, H ^d   Giannobile, W V ^a,b  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VLST Corporation   (United States)

^d Targeted Genetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; DEOXYRIBONUCLEASE I; FC RECEPTOR; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FUSION GENE; GENE TARGETING; MALE; NONHUMAN; OSTEOLYSIS; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; PSEUDOTYPING; RAT; SEROTYPE;

ALVEOLAR BONE LOSS; ALVEOLAR PROCESS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE DENSITY; CELL DIFFERENTIATION; CYTOKINES; DEPENDOVIRUS; DISEASE PROGRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; OSTEOCLASTS; PERIODONTITIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TUMOR NECROSIS FACTOR;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PORPHYROMONAS GINGIVALIS; RATTUS;

EID: 62549149852     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.174     Document Type: Article

References (53)

1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet 2005; 366: 1809-1820.
2. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs Jr DR, Sacco RL et al. Periodontal microbiota and carotid intimamedia thickness: The Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111: 576-582.
3. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680.
4. Giannobile WV. Host-response therapeutics for periodontal diseases. J Periodontol 2008; 79: 1592-1600.
5. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 2003; 8: 12-37.
6. Graves DT, Cochran D. The contribution of interleukin-1 and tumor necrosis factor to periodontal tissue destruction. J Periodontol 2003; 74: 391-401.
7. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275: 4858-4864.
8. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
9. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998; 9: 248-266.
10. Graves DT, Oskoui M, Volejnikova S, Naguib G, Cai S, Desta T et al Tumor necrosis factor modulates fibroblast apoptosis, PMN recruitment, and osteoclast formation in response to P. gingivalis infection. J Dent Res 2001; 80: 1875-1879.
11. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 2005; 202: 589-595.
12. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S et al Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-286.
13. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K et al. A physical and functional map of the human TNF-alpha/ NF-kappa B signal transduction pathway. Nat Cell Biol 2004; 6 97-105.
14. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998; 160: 943-952.
15. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997; 100 1557-1565.
16. Garlet GP, Cardoso CR, Campanelli AP, Ferreira BR, Avila-Campos MJ, Cunha FQ et al. The dual role of p55 tumour necrosis factor-alpha receptor in Actinobacillus actinomycetemcomitans-induced experimental periodontitis: Host protection and tissue destruction. Clin Exp Immunol 2007; 147: 128-138.
17. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004; 363: 675-681.
18. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63 508-516.
19. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T et al Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50: 353-363.
20. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006; 355: 704-712.
21. van der Heijde DM. Overview of radiologic efficacy of new treatments. Rheum Dis Clin North Am 2004; 30: 285-293.
22. Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 2006; 54: 76-81.
23. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998; 160: 403-409.
24. Delima AJ, Oates T, Assuma R, Schwartz Z, Cochran D, Amar S et al. Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J Clin Periodontol 2001; 28: 233-240.
25. Graves DT, Delima AJ, Assuma R, Amar S, Oates T, Cochran D. Interleukin-1 and tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration toward alveolar bone in experimental periodontitis. J Periodontol 1998; 69: 1419-1425.
26. Oates TW, Graves DT, Cochran DL. Clinical, radiographic and biochemical assessment of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin Periodontol 2002; 29: 137-143.
27. Lima V, Vidal FD, Rocha FA, Brito GA, Ribeiro RA. Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats. J Periodontol 2004; 75: 162-168.
28. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001; 13: 164-169.
29. Chan JM, Villarreal G, Jin WW, Stepan T, Burstein H, Wahl SM. Intraarticular gene transfer of TNFR:FC suppresses experimental arthritis with reduced systemic distribution of the gene product. Mol Ther 2002; 6: 727-736.
30. Sandalon Z, Bruckheimer EM, Lustig KH, Burstein H. Longterm suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:FC Vector. Mol Ther 2007; 15: 264-269.
31. Muthukuru M, Jotwani R, Cutler CW. Oral mucosal endotoxin tolerance induction in chronic periodontitis. Infect Immun 2005; 73: 687-694.
32. WHO. Adherence to long-term therapies. Evidence for action. World Health Organization 2003. Available from: http://www.who.int/ mediacentre/releases/2003/pr2054/en/.
33. Warrington Jr KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006; 119: 571-603.
34. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: A review. J Periodontol 2005; 76: 2066-2074.
35. Socransky SS, Haffajee AD. The bacterial etiology of destructive periodontal disease: Current concepts. J Periodontol 1992; 63 322-331.
36. Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR et al. Porphyromonas gingivalis lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. Infect Immun 2004; 72: 5041-5051.
37. Broad A, Jones DE, Kirby JA. Toll-like receptor (TLR) response tolerance: A key physiological 'damage limitation' effect and an important potential opportunity for therapy. Curr Med Chem 2006; 13: 2487-2502.
38. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 2005; 77: 3-15.
39. Ridderstad A, Abedi-Valugerdi M, Moller E. Cytokines in rheumatoid arthritis. Ann Med 1991; 23: 219-223.
40. Nanes MS. Tumor necrosis factor-alpha: Molecular and cellular mechanisms in skeletal pathology. Gene 2003; 321: 1-15.
41. Liu D, Xu JK, Fibliomeni L, Huang L, Pavlos NJ, Rogers M et al. Expression of RANKL and OPG mRNA in periodontal disease: Possible involvement in bone destruction. Int J Mol Med 2003; 11: 17-21.
42. Wara-aswapati N, Surarit R, Chayasadom A, Boch JA, Pitiphat W. RANKL upregulation associated with periodontitis and Porphyromonas gingivalis. J Periodontol 2007; 78: 1062-1069.
43. Nagasawa T, Kobayashi H, Kiji M, Aramaki M, Mahanonda R, Kojima T et al. LPS-stimulated human gingival fibroblasts inhibit the differentiation of monocytes into osteoclasts through the production of osteoprotegerin. Clin Exp Immunol 2002; 130: 338-344.
44. Almasri A, Wisithphrom K, Windsor LJ, Olson B. Nicotine and lipopolysaccharide affect cytokine expression from gingival fibroblasts. J Periodontol 2007; 78: 533-541.
45. Wada N, Maeda H, Yoshimine Y, Akamine A. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 2004; 35: 629-635.
46. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275: 768-775.
47. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006; 169 987-998.
48. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
49. Teng YT. Protective and destructive immunity in the periodontium: Part 2 - T-cell-mediated immunity in the periodontium. J Dent Res 2006; 85: 209-219.
50. Sandalon Z, Bruckheimer EM, Lustig KH, Rogers LC, Peluso RW, Burstein H. Secretion of a TNFR:FC fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol 2004; 78 12355-12365.
51. Gao GP, Qu G, Faust LZ, Engdahl RK, Xiao W, Hughes JV et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9: 2353-2362.
52. Darveau RP, Hancock RE. Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 1983; 155: 831-838.
53. Park CH, Abramson ZR, Taba Jr M, Jin Q, Chang J, Kreider JM et al. Three-dimensional micro-computed tomographic imaging of alveolar bone in experimental bone loss or repair. J Periodontol 2007; 78: 273-281.